Published on 25 February 2013
Ablynx and Spirogen enter into a research collaboration
Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. have announced a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen’s proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary technology platform.
Under the terms of the collaboration, Ablynx will provide access to novel Nanobodies against a specific, undisclosed cancer target and Spirogen will provide access to its proprietary cytotoxic warheads (PBDs) and conjugation technologies. Both companies will contribute their resources towards the collaboration, which is expected to last for up to a year initially. Following this feasibility phase, Ablynx will have the option to either in-license Spirogen’s technology or, in collaboration with Spirogen, move development forward with a third party. No further terms have been disclosed.